| Gene
Expressed |
Increase
in Productivity |
Status
of Project |
Recombinant
Human Factor VIII:C Protein
(Genentech) |
The
process developed resulted in a 100 fold increase in production
of full length FVIII:C and allowed for expression of new
variants at a level 1000 fold above the original process. |
FVIII:C
was licensed to Bayer Biotechnology and is currently marketed as
a clotting factor widely used in the treatment of hemophilia. |
Nerve
Growth Factor
(Genentech) |
Established the first viable
mammalian production cell line for NGF |
Because of poor results in Phase III
in 1999, clinical further clinical devleopment was abandoned. |
Anti-HER2
Humanized Monoclonal Antibody
(Genentech) |
Developed a system at allow for rapid production of humanized
antibodies. This process cut the time it took to develop a
production cell line from 9 months to 3 months. |
Genentech has commercialized the anti-HER2 antibody as a
treatment for metastatic breast cancer. |
| Anti-IgE
Humanized Monoclonal Antibody (Genentech) |
Developed a system to allow for
rapid production of variants of humanized antibodies to for in
vivo efficacy testing. The small-scale transient process
developed allowed production of sufficient protein (in the
milligram range) in a week rather than 3 months. |
Genentech is investigating whether
the anti-IgE humanized monoclonal
antibody can interfere early in the complex, multistep process
that lead to the symptoms of allergy, in patients
who have asthma. Xolain was awaiting
FDA approval (8/01). |
